Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Current Assets (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Current Assets data on record, last reported at $8.8 million in Q4 2025.

  • For Q4 2025, Current Assets rose 60.67% year-over-year to $8.8 million; the TTM value through Dec 2025 reached $8.8 million, up 60.67%, while the annual FY2025 figure was $12.9 million, 48.08% up from the prior year.
  • Current Assets reached $8.8 million in Q4 2025 per INM's latest filing, down from $10.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $16.0 million in Q3 2021 and bottomed at $5.5 million in Q4 2024.
  • Average Current Assets over 5 years is $10.3 million, with a median of $10.4 million recorded in 2024.
  • Peak YoY movement for Current Assets: plummeted 53.68% in 2024, then surged 60.67% in 2025.
  • A 5-year view of Current Assets shows it stood at $12.5 million in 2021, then grew by 12.1% to $14.0 million in 2022, then dropped by 15.75% to $11.8 million in 2023, then tumbled by 53.68% to $5.5 million in 2024, then soared by 60.67% to $8.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $8.8 million in Q4 2025, $10.8 million in Q3 2025, and $12.9 million in Q2 2025.